MYC and Burkitt lymphoma: Exploiting this notion, we found that treating human Burkitt lymphoma cell lines (Raji and CA46) with the HSP90 inhibitors, 17-AAG or 17-DMAG, decreased MYC expression levels by reducing both MYC mRNA and protein levels, subsequently diminishing tumor cell proliferation causing cell cycle arrest, and increasing necrosis and apoptosis.